Minireview: Epigenetic Changes in Ovarian Cancer

Author:

Balch Curt123,Fang Fang1,Matei Daniela E.14,Huang Tim H.-M.5,Nephew Kenneth P.12364

Affiliation:

1. Medical Sciences (C.B., F.F., K.P.N.), School of Medicine, Indiana University, Bloomington, Indiana 47405

2. Melvin and Bren Simon Cancer Center (C.B., D.E.M., K.P.N.), Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202

3. Department of Cellular and Integrative Physiology (C.B., K.P.N.), Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202

4. Division of Hematology/Oncology (D.E.M., K.P.N.), Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202

5. The Human Cancer Genetics Program (T.H.-M.H.), Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210

6. Department of Obstetrics and Gynecology (K.P.N.), Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202

Abstract

Abstract Epigenetic aberrations, including DNA methylation, histone modifications, and micro-RNA dysregulation, are now well established in the development and progression of ovarian cancer, and their gradual accumulation is associated with advancing disease stage and grade. Epigenetic aberrations are relatively stable, associated with distinct disease subtypes, and present in circulating serum, representing promising diagnostic, prognostic, and pharmacodynamic biomarkers. In contrast to DNA mutations and deletions, aberrant gene-repressive epigenetic modifications are potentially reversible by epigenetic therapies, including inhibitors of DNA methylation or histone-modifying enzymes. Although epigenetic monotherapies have not shown activity against solid tumors, including ovarian cancer, preclinical studies suggest they will be effective when used in combination with one another or with conventional chemotherapeutics, and combinatorial epigenetic therapy regiments are being examined in cancer clinical trials. A greater understanding of the role of epigenetics in ovarian neoplasia will provide for improved interventions against this devastating malignancy.

Publisher

The Endocrine Society

Subject

Endocrinology

Reference92 articles.

1. Cancer statistics, 2008.;Jemal;CA Cancer J Clin,2008

2. Cancer of the ovary.;Liu;N Engl J Med,2005

3. The epigenomics of cancer.;Jones;Cell,2007

4. The context and potential of epigenetics in oncology.;Lopez;Br J Cancer,2009

5. The mammalian epigenome.;Bernstein;Cell,2007

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3